In this interview at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Hagop Kantarjian, MD, professor of leukemia at the University of Texas MD Anderson Cancer Center, interviews Tara Graff, DO, director of clinical research at Mission Cancer and Blood at Iowa Health Care, on the cohort of patients with marginal zone lymphoma (MZL) enrolled in the phase 2 MorningSun trial.
The trial, which investigated the efficacy and safety of frontline subcutaneous mosunetuzumab, a CD20/CD30-directed bispecific antibody, was part of the MorningSun basket trial. In MZL, chemoimmunotherapy remains standard of care, but investigators are hoping to move to chemo-free regimens with novel therapies.
In the subcutaneous formulation, mosunetuzumab had no grade 5 adverse events and investigators reported no immune effector cell-associated neurotoxicity syndrome in patients.
Dr. Graff recalled the treatment progress of one of the patients.
“She completed her 17 cycles in September of 2023… and she remains in a complete remission,” Dr. Graff said.
